AI drug discovery company Isomorphic Labs is in talks to raise about $5 billion in funding, with a valuation potentially reaching $50 billion.

BlockBeats news, November 5 — Alphabet's AI drug discovery company Isomorphic Labs is in talks for a new funding round of approximately $5 billion, corresponding to a valuation of about $50 billion. People familiar with the matter said the financing has not been finalized and details may change.

Isomorphic Labs was spun out of Google DeepMind by Demis Hassabis in 2021 and is headquartered in London. Its core business is using AI (based on technologies such as AlphaFold) to accelerate drug design and discovery.

The company just completed a $2.1 billion Series B funding round in May this year, led by Thrive Capital with participation from Alphabet and others. Bloomberg previously reported in October that the company was in early-stage funding talks, with a valuation range of $40 billion to $50 billion. The company is still in the preclinical stage, and Hassabis previously said it expects to enter its first clinical trial by the end of 2026.